Physician

Francisco A Castillos, MD

According to 2025 Medicare claims, Francisco Castillos, MD (NPI: 1619978285) practices hematology/oncology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is PERSONALIZED HEMATOLOGY-ONCOLOGY OF WAKE FOREST PLLC (NPI: 1053679944; TIN: 454188515) and primary practice location at 27587-6298.

Castillos' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 360 traditional Medicare patients, billed 133,746 HCPCS/CPT codes, and received $913,744 in Medicare payments. The top billing code was 82728 (Ferritin (blood protein) level). Part D data shows 982 prescription claims across 183 beneficiaries totaling $1,984,779 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 11 claims. Open Payments data shows 72 records totaling $1,627. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $232,347 to $913,744. Similarly, Part D prescription costs have moved sharply higher in recent years, from $425,532 to $1,984,779. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $8,233 and ending at $4,319.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	487	17,866	$232,347
2016	355	22,528	$296,753
2017	354	74,033	$424,971
2018	352	390,684	$708,144
2019	285	508,731	$834,735
2020	244	394,855	$1,080,966
2021	299	212,009	$846,105
2022	338	92,069	$886,856
2023	325	71,757	$947,176
2024	360	133,746	$913,744

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	174	1,825	$425,532
2016	169	1,953	$510,029
2017	163	2,104	$628,596
2018	164	1,955	$784,037
2019	175	1,963	$990,556
2020	152	1,812	$828,200
2021	155	1,651	$844,969
2022	198	1,516	$2,062,120
2023	190	1,214	$1,992,859
2024	183	982	$1,984,779

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	56	$4,315
2016	N/R	105	$4,993
2017	N/R	62	$1,936
2018	N/R	63	$5,933
2019	N/R	47	$2,179
2020	N/R	14	$500
2021	13	56	$1,377
2022	N/R	77	$2,750
2023	N/R	62	$3,770
2024	N/R	11	$150

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82728	Ferritin (blood protein) level	205	324	$13
83550	Iron binding capacity	210	440	$9
80048	Blood test, basic group of blood chemicals (calcium, total)	248	616	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	254	864	$8
83540	Iron level	211	442	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	26	780	$462,862
Imbruvica	Ibrutinib	24	672	$390,307
Promacta	Eltrombopag Olamine	13	390	$97,967
Procrit	Epoetin Alfa	24	644	$60,777
Deferasirox	Deferasirox	12	360	$34,491

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A7038	Filter, disposable, used with positive airway pressure device	N	N/R	11	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	72	$1,627	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Francisco A. Castillos, MD?

Tedicare shows public-source Medicare data for Francisco A. Castillos, MD (NPI 1619978285), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Francisco A. Castillos, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Francisco A. Castillos, MD?

Francisco A. Castillos, MD is linked to PERSONALIZED HEMATOLOGY-ONCOLOGY OF WAKE FOREST PLLC (billing NPI 1053679944) in the available physician profile data.

Does Francisco A. Castillos, MD have Open Payments data?

Francisco A. Castillos, MD has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.